File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Efficacy of sucralfate in corpus, prepyloric, and duodenal ulcer-associated gastric ulcers. A double-blind, placebo-controlled study

TitleEfficacy of sucralfate in corpus, prepyloric, and duodenal ulcer-associated gastric ulcers. A double-blind, placebo-controlled study
Authors
Issue Date1985
PublisherExcerpta Medica, Inc. The Journal's web site is located at http://www.elsevier.com/locate/amj
Citation
American Journal Of Medicine, 1985, v. 79 n. 2 C, p. 24-31 How to Cite?
AbstractA 12-week study with two weekly endoscopic assessments was performed in 138 patients to compare the efficacy of sucralfate fine granules (900 mg one-half hour before breakfast, lunch, and dinner, and at bedtime) versus placebo in the healing of gastric ulcers prestratified into corpus, prepyloric, and duodenal ulcer-associated. For corpus and prepyloric ulcers, the respective healing rates achieved by sucralfate at six weeks (69 and 80 percent) and at eight weeks (80 and 93 percent) were significantly (p < 0.005) better than those obtained with placebo (33 and 25 percent at six weeks, and 41 and 33 percent at eight weeks). The design of the study permitted life-table analysis that further demonstrated the efficacy of sucralfate in these two ulcer types (p < 0.0001). Symptomatic response was likewise significantly better than with placebo. Similar healing rates and symptomatic responses were observed for patients with duodenal ulcer-associated gastric ulcer but were not significantly better with sucralfate than with placebo. From 38 prospectively obtained clinical, personal, physiological, and endoscopic characteristics, it was found that ulcer size and a history of pain had significant influence on healing with sucralfate. It is concluded that sucralfate is safe and effective for the treatment of corpus and prepyloric ulcers.
Persistent Identifierhttp://hdl.handle.net/10722/161691
ISSN
2015 Impact Factor: 5.61
2015 SCImago Journal Rankings: 2.023
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLam, SKen_US
dc.contributor.authorLau, WYen_US
dc.contributor.authorLai, CLen_US
dc.date.accessioned2012-09-05T05:14:00Z-
dc.date.available2012-09-05T05:14:00Z-
dc.date.issued1985en_US
dc.identifier.citationAmerican Journal Of Medicine, 1985, v. 79 n. 2 C, p. 24-31en_US
dc.identifier.issn0002-9343en_US
dc.identifier.urihttp://hdl.handle.net/10722/161691-
dc.description.abstractA 12-week study with two weekly endoscopic assessments was performed in 138 patients to compare the efficacy of sucralfate fine granules (900 mg one-half hour before breakfast, lunch, and dinner, and at bedtime) versus placebo in the healing of gastric ulcers prestratified into corpus, prepyloric, and duodenal ulcer-associated. For corpus and prepyloric ulcers, the respective healing rates achieved by sucralfate at six weeks (69 and 80 percent) and at eight weeks (80 and 93 percent) were significantly (p < 0.005) better than those obtained with placebo (33 and 25 percent at six weeks, and 41 and 33 percent at eight weeks). The design of the study permitted life-table analysis that further demonstrated the efficacy of sucralfate in these two ulcer types (p < 0.0001). Symptomatic response was likewise significantly better than with placebo. Similar healing rates and symptomatic responses were observed for patients with duodenal ulcer-associated gastric ulcer but were not significantly better with sucralfate than with placebo. From 38 prospectively obtained clinical, personal, physiological, and endoscopic characteristics, it was found that ulcer size and a history of pain had significant influence on healing with sucralfate. It is concluded that sucralfate is safe and effective for the treatment of corpus and prepyloric ulcers.en_US
dc.languageengen_US
dc.publisherExcerpta Medica, Inc. The Journal's web site is located at http://www.elsevier.com/locate/amjen_US
dc.relation.ispartofAmerican Journal of Medicineen_US
dc.subject.meshActuarial Analysisen_US
dc.subject.meshAluminum - Therapeutic Useen_US
dc.subject.meshAnti-Ulcer Agents - Therapeutic Useen_US
dc.subject.meshClinical Trials As Topicen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshDuodenal Ulcer - Complicationsen_US
dc.subject.meshFemaleen_US
dc.subject.meshGastroscopyen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPatient Complianceen_US
dc.subject.meshPlacebosen_US
dc.subject.meshRandom Allocationen_US
dc.subject.meshStomach Ulcer - Complications - Drug Therapy - Pathologyen_US
dc.subject.meshSucralfateen_US
dc.titleEfficacy of sucralfate in corpus, prepyloric, and duodenal ulcer-associated gastric ulcers. A double-blind, placebo-controlled studyen_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/0002-9343(85)90568-6-
dc.identifier.pmid3898832-
dc.identifier.scopuseid_2-s2.0-0022252238en_US
dc.identifier.volume79en_US
dc.identifier.issue2 Cen_US
dc.identifier.spage24en_US
dc.identifier.epage31en_US
dc.identifier.isiWOS:A1985ARC1800005-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLam, SK=7402279473en_US
dc.identifier.scopusauthoridLau, WY=7402933199en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats